On the other hand, some studies have shown that FGFR-3 is not overexpressed in benign prostatic hyperplasia as well as in prostate cancer itself [55–57] corroborating our results that showed that the levels of this receptor decrease with the advancement of this malignant disease. Here, FGFR3 is linked to prostate carcinoma.